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Abstract
Objectives: Microbial translocation (MT) through the gut accounts for immune activation and CD4+ loss in HIV and may
influence HCV disease progression in HIV/HCV co-infection. We asked whether increased MT and immune activation may
hamper anti-HCV response in HIV/HCV patients.
Methods: 98 HIV/HCV patients who received pegylated-alpha-interferon (peg-INF-alpha)/ribavirin were retrospectively
analyzed. Baseline MT (lipopolysaccharide, LPS), host response to MT (sCD14), CD38+HLA-DR+CD4+/CD8+, HCV genotype,
severity of liver disease were assessed according to Early Virological Response (EVR: HCV-RNA ,50 IU/mL at week 12 of
therapy or $2 log10 reduction from baseline after 12 weeks of therapy) and Sustained Virological Response (SVR: HCV-RNA
,50 IU/mL 24 weeks after end of therapy). Mann-Whitney/Chi-square test and Pearson’s correlation were used.
Multivariable regression was performed to determine factors associated with EVR/SVR.
Results: 71 patients displayed EVR; 41 SVR. Patients with HCV genotypes 1–4 and cirrhosis presented a trend to higher
sCD14, compared to patients with genotypes 2–3 (p=0.053) and no cirrhosis (p=0.052). EVR and SVR patients showed
lower levels of circulating sCD14 (p=0.0001, p=0.026, respectively), but similar T-cell activation compared to Non-EVR (Null
Responders, NR) and Non-SVR (N-SVR) subjects. sCD14 resulted the main predictive factor of EVR (0.145 for each sCD14 unit
more, 95%CI 0.031–0.688, p=0.015). SVR was associated only with HCV genotypes 2–3 (AOR 0.022 for genotypes 1–4 vs 2–3,
95%CI 0.001–0.469, p=0.014).
Conclusions: In HIV/HCV patients sCD14 correlates with the severity of liver disease and predicts early response to peg-INF-
alpha/ribavirin, suggesting MT-driven immune activation as pathway of HIV/HCV co-infection and response to therapy.
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Introduction
Up to 25–50% of HIV-positive patients are co-infected with
HCV [1,2]. In the setting of HIV disease, clinical manifestations of
HCV infection are severe, leading to rapid liver damage and
cirrhosis [3–8]. Indeed, liver-related mortality is a leading cause of
death in HIV-infected population [9–11].
Following current standard treatment of HCV infection with
pegylated-interferon-alpha (peg-INF-alpha) plus ribavirin, HCV
mono-infected patients reach a sustained virologic response (SVR)
with eradication of the virus in 50–80% of cases;conversely,the rate of
SVR is substantially lower in HIV/HCV co-infected subjects [12,13].
Despite several factors have been associated with response to anti-
HCV therapy, the determinants of successful outcome of full course
peg-INF-alpha/ribavirin therapy are still scantily defined [14–18].
No HCV-RNA decrease $2 log10 after 3 months of treatment,
that is called ‘‘null response’’ (NR), is associated with a .95%
probability of no sustained response and has recently been
associated with a very low response to retreatment with triple
therapies including peg-INF-alpha/ribavirin/anti-HCV protease
inhibitors [18–22]. Conversely, HCV-RNA decrease $2 log10
after 3 months of treatment, i.e. Early Virologic Response (EVR),
has a positive predictive value on SVR of 72–84% [19,20].
During HIV infection, a dramatic depletion of CD4+ T cells in
the gut occurs [23], leading to the speculation that injury to the
immune component of the gastrointestinal mucosal surface may
induce increased translocation of microbial products in the
systemic circulation, particularly LPS, despite a direct cause-effect
nexus between gut mucosa disruption and microbial translocation
has not been established yet [24]. Increased levels of circulating
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the pathogenesis of disease progression and CD4+ lymphopenia
[24–26].
Recently, the role of LPS has also been analyzed as a possible
underlying cause of liver disease. Subjects with HCV mono-
infection display a high degree of microbial translocation (MT)
and elevated LPS levels are strongly associated with the severity of
liver disease [27,28]; likewise, augmented plasma LPS also features
non-alcoholic fatty liver disease [29–31]. Furthermore, in animal
models LPS appears to accelerate liver fibrosis, both directly by
increasing hepatic fibrosis and stimulating liver Kupffer cells, and
indirectly by enhancing immune activation [32,33].
Given the importance of early predictive parameters of
therapeutic efficacy, and above all, of EVR, in order to limit the
frequent side effects of drug exposure in patients unlikely to benefit
from treatment, we sought to investigate whether measures of MT
before the initiation of anti-HCV treatment correlates with EVR
and/or SVR to HCV therapy in HIV/HCV co-infected patients.
Materials and Methods
Study design and population
We retrospectively analyzed chronic HIV/HCV co-infected
patients attending the Institute of Infectious and Tropical Diseases,
University of Brescia at ‘‘Spedali Civili’’, Brescia and the Clinic of
Infectious Diseases, University of Milan at ‘‘San Paolo’’ Hospital
in Milan, Italy between January 2005 and December 2009. This
study was approved by the Ethic Committees of the University of
Brescia at ‘‘Spedali Civili’’, Brescia and of the University of Milan
at ‘‘San Paolo’’ Hospital. Each patient gave written informed
consent to blood collection for research purpose, upon approval of
the form by Local Ethic Committee.
Inclusion criteria were to have initiated at least one dose of a
treatment including peg-INF-alpha 2a and 2b subcutaneously
once weekly (180 mcg or 1.5 mcg/Kg) plus daily weight-dosed
ribavirin (1000 mg/day for a pretreatment weight ,75 Kg or
1200 mg/day for weight $75 Kg).
According to the virological response at week 12 of treatment,
patients were considered: (i) Early Virological Responders (EVR),
undetectable serum HCV-RNA (,50 IU/mL) or $2 log10
reduction from baseline after 12 weeks of therapy; (ii) Null
Responders (NR), serum HCV-RNA $50 IU/mL and ,2 log10
reduction from baseline.
SVR was defined as undetectable serum HCV-RNA (,50 IU/
mL) 24 weeks after the end of a full course of 48 or 72 weeks of
anti-HCV treatment, according to genotype. Baseline was defined
as time of anti-HCV treatment introduction (within one month
before the beginning of therapy). Subjects who were lost at follow-
up before week 12 or before the time point established for SVR
assessment were considered NR patients and Sustained Virological
Non Responders (N-SVR patients), respectively.
Staging of liver disease
The stage of liver disease was determined in a subgroup of
patients who underwent percutaneous liver biopsies, or liver
stiffness by transient elastography (FibroScanH, Echo Sense Paris,
France). Only the examinations with an Interquartile Range below
30% of the median value and a success rate of acquisition above
60% were considered [34]. The Ishak-modified Knodell score
system (2000) was used to assess necro-inflammatory activity and
fibrosis. Advanced fibrosis was defined as Knodell score F3–4 on
liver biopsy or liver stiffness greater than 12.5 kPa on Fibroscan.
Hepatic cirrhosis was defined as the presence of a histopatholog-
ical diagnosis, a liver surface nodularity assessed by ultrasound or a
liver stiffness greater than 17 kPa.
MT and immune activation analysis
LPS and sCD14 plasma levels were quantified on fasting
samples with commercially available kits (Limulus Amebocyte
Assay, Cambrex, Italy; ELISA assay, R&D, Milan, Italy) as
previously described [25].
Activated HLA-DR+CD38+CD4+/CD8+ were evaluated on
thawed PBMCs: HLA-DR fluorescein isothiocyanate (FITC),
CD38 phycoerytrin (PE), CD4 PerCPcyanin 5.5 (PerCPCy 5.5),
CD8 PerCPcyanin 5.5 (PerCPCy 5.5) (Becton Dickinson, San
Jose `, CA, USA). The following combinations were used: CD4/
HLA-DR/CD38, CD8/HLA-DR/CD38. The proportion of
HLA-DR+CD38+ was calculated on gated CD4+ and CD8+ T-
cells.
Statistical analysis
Baseline differences between patients’ groups were assessed
using Mann-Whitney non-parametric U test and Chi-squared test
for continuous and categorical variables, respectively. Comparison
of MT and immune activation between patients with HCV
genotypes 1–4 versus 2–3, absence-moderate versus advanced
fibrosis, cirrhosis versus not cirrhosis, EVR versus NR and SVR
versus N-SVR patients were evaluated by Mann-Whitney U test.
Multivariable logistic regression model was used to identify
baseline parameters that were independently associated with
EVR or SVR. Multivariate analysis was performed in 65/98
patients for whom all the clinical, epidemiological and biological
parameters under study were available. Factors considered in the
logistic regression model were age, sex, baseline CD4+ T cell
count, HCV genotypes, HCV-RNA, fibrosis, cirrhosis and MT.
Analyses were performed using SPSS software (version 18).
Results
Study population
Ninety-eight HIV/HCV co-infected patients undergoing anti-
HCV treatment were enrolled. Table 1 shows the clinical,
epidemiological, and laboratory data of the patients under study.
71 patients (72.5%) achieved EVR; 27 subjects (27.5%) displayed
NR. Eight out of 98 patients stopped HCV therapy before 12
weeks and were lost at follow up (Table 1).
Patients’ groups were comparable for demographic, HIV
related variables, and metabolic parameters (Table 1).
MT and HCV related parameters
Plasma LPS and sCD14 levels were assessed in a subgroup of
unselected patients for whom plasma samples were available (65
and 91 samples, respectively). Baseline characteristics of the 65
and 91 patients for whom LPS and sCD14 measurements were
performed were comparable to the main population under study.
Compared to initial-moderate hepatic disease, the presence of
advanced hepatic fibrosis was not associated with higher sCD14
levels [median sCD14, patients with advanced hepatic fibrosis: 3,
(IQR 2.53–3.66) - patients with initial-moderate hepatic disease:
2.77, (IQR 2.25–3.48), p=0.128], (Figure 1a).
Patients with cirrhosis were characterized by a trend to higher
sCD14 plasma levels, albeit not reaching statistical significance
[median sCD14, patients with cirrhosis: 3.09, (IQR 2.62–4.22) -
patients without cirrhosis: 2.79, (IQR 2.29–3.44), p=0.052],
(Figure 1c).
Similarly, patients with HCV genotypes 1–4 tended to display
higher sCD14 [median sCD14, HCV genotype 1–4: 3.07, (IQR
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(Figure 1e). Aiming to further investigate the association between
circulating sCD14 and HCV genotype, we performed 2
sensitivity analyses: i) excluding patients with advanced fibrosis;
ii) excluding patients with cirrhosis. Most interestingly, patients
with genotypes 1–4 still displayed significantly higher circulating
sCD14 according to both i) and ii) analyses [i): median sCD14,
HCV genotype 1–4: 3.1, (IQR 2.6–3.7) - HCV genotype 2–3:
2.6, (IQR 1.9–2.8), p=0.022; ii): median sCD14, HCV genotype
1–4: 3.07, (IQR 2.6–3.7) - HCV genotype 2–3: 2.63, (IQR 2.1–
3.2), p=0.028].
As shown in Figure 1b, d and f, no significant association was
shown between LPS levels and advanced fibrosis, cirrhosis and
HCV genotypes.
Table 1. Baseline demographic and immuno-virological characteristics of study population.
Characteristics Patients (98) EVR (71) NR (27) p (EVR vs NR)
Age, years * 44 (41–46) 44 (41–46) 43 (40–46) 0.461
Gender, male u 81 (82.7) 57 (80.3) 24 (88.9) 0.385
Time since 1
st diagnosis of HIV, (years) * 18 (13–20) 18 (13–21) 19 (12–20) 0.466
Duration of cART, (years) * 10 (8–13) 10 (8–14) 10 (5–12) 0.592
cART u 0.845
Naive 2 (2) 1 (1.5) 1 (3.7)
NNRTI+NRTI 14 (14.3) 11 (15.5) 3 (11.1)
NRTI+PI 74 (75.5) 53 (74.6) 21 (77.8)
Other 8 (8.2) 6 (8.4) 2 (7.4)
Exposure cathegories u 0.778
MSM 3 (3) 2 (2.8) 1 (3.7)
WSM 8 (8.2) 5 (7) 3 (11.1)
IDUs 87 (88.8) 64 (90.2) 23 (85.2)
Previous AIDS diagnosis u 24/93 (25.8) 14/67 (20.9) 10/26 (38.5) 0.082
CD4+ T cells/mL nadir * 152 (67.5–251.5) 173 (106.5–258.5) 100 (36–198) 0.045
Baseline CD4+ T cells/mL * 430 (321.5–567) 433 (321–555) 428 (300–687) 0.659
CD4+ T cells % * 26.9 (21.9–33) 27.6 (22.1–33.7) 25 (19.9–29.1) 0.274
CD8+ T cells/mL * 601.5 (467.5–939) 626 (429–900) 589 (492–1132) 0.556
CD8+ T cells % * 40.9 (33.9–47) 40.3 (33.6–47) 41.2 (34.1–48.5) 0.578
Baseline HIV-RNA
log10 cp/mL *
1.7 1.7 1.7 0.893
Time to HIV-RNA
,40 cp/mL (months)*
41 (20–69) 41 (18–72.2) 43 (20–58.7) 0.569
HCV genotypes u 0.0001
1–4 45 (45.9) 23 (32.4) 22 (81.5)
2–3 53 (54.1) 48 (67.6) 5 (18.5)
Baseline HCV-RNA
log10 IU/mL *
5.5 (4.9–6.03) 5.6 (4.8–5.8) 5.8 (5.2–6.5) 0.015
Cirrhosis u 30/94 (31.2) 18/69 (26.1) 12/25 (48) 0.044
Advanced fibrosis u 43/89 (48.3) 29/66 (43.9) 14/23 (60.9) 0.162
HBV infection (HBsAg+) u 7 (7.1) 4 (5.6) 3 (11.1) 0.390
Serum AST (UI/L) * 109.8 (42.2–94) 67 (42–94) 71 (42–103) 0.972
Serum ALT (UI/L) * 89 (55–137.2) 97 (51–145) 85 (58–110) 0.548
BMI * 22.9 (21.2–25.1) 22.9 (21.1–25.4) 22.8 (21.6–25.6) 0.320
Glycemia (mg/dL) * 89 (83–97.5) 90 (83.7–101.7) 88 (79.2–96.5) 0.492
Insulinemia (UI/L) * 12.9 (9.4–20.1) 13 (9.4–20.6) 11 (8.1–18.2) 0.526
Alcol (gr/die) * 0 (0–11) 0 (0–10) 0 (0–5) 0.755
HOMA index * 2.6 (1.7–4.1) 2.5 (1.7–4) 2.9 (1.6–4.3) 0.972
LEGEND. Data are presented as *median, (IQR) and uabsolute number, (%). Differences between groups were compared by *Mann Whitney U test and ux2 test. EVR,
Early Virological Response: undetectable serum HCV-RNA (,50 IU/mL) or $2l o g 10 reduction from baseline after 12 weeks of therapy; NR, Null Responders: serum HCV-
RNA $50 IU/mL and ,2l o g 10 reduction from baseline. cART, Combination Antiretroviral therapy; NRTI, Nucleoside Reverse Transcriptase Inhibitors; NNRTI, Non
Nucleoside Reverse Transcriptase Inhibitors; PI, Protease Inhibitors. MSM, men who have sex with men; WSM, women who have sex with men; IDUs, injection drug users.
HCV, hepatitis C virus; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen. AST, aspartate aminotransferase; ALT, alanine aminotransferase. BMI, Body Mass Index.
HOMA index, Homeostatic Model Assessment index.
doi:10.1371/journal.pone.0032028.t001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32028Figure 1. Higher microbial translocation is associated with HCV genotypes 1–4 and cirrhosis. a)-b) sCD14 and LPS were compared
between patients with advanced fibrosis (AF) and non advanced fibrosis (N-AF). c)-d) sCD14 and LPS were compared between patients with cirrhosis
and absence of cirrhosis (N-Cirrhosis). e)-f) sCD14 and LPS were compared between patients with HCV genotypes 1–4 and genotypes 2–3. Each point
represents the value from one subject’s plasma. sCD14 and LPS were measured in plasma samples; sCD14 mg/mL, LPS pg/mL. AF=advanced fibrosis
– N-AF=non advanced fibrosis. p-values were assessed by Mann Whitney U test. p.0.05 was considered non significant (NS).
doi:10.1371/journal.pone.0032028.g001
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We studied HLA-DR and CD38 expression on CD4+ and
CD8+ T cells in an unselected subgroup of 53 patients for whom
PBMC samples were available. Baseline characteristics of this
subgroup of patients were comparable to the main population
under study.
Comparable activated T cell numbers were shown in patients
with advance fibrosis compared to those with absent or initial-
moderate fibrosis [HLA-DR+/CD38+/CD4+, advanced fibrosis:
30.8, (IQR 13.9–46.8) - absence or initial-moderate fibrosis: 25.8,
(IQR 16.2–43.5), p=0.957; HLA-DR+/CD38+/CD8+, ad-
vanced fibrosis: 39.9, (IQR 21.8–63.8) - absence or initial-
moderate fibrosis: 41.01, (IQR 28.6–53.2), p=0.513] (Figure 2a,
b) and in patients with cirrhosis compared to subjects not
displaying cirrhosis [HLA-DR+/CD38+/CD4+, cirrhosis: 28.9,
(IQR 13.3–47.8) – absence of cirrhosis: 25.8, (IQR 16.2–44.1),
p=0.971; HLA-DR+/CD38+/CD8+, cirrhosis: 41.9, (IQR 23.6–
69.2) – absence of cirrhosis: 41.1, (IQR 27.1–56.2), p=0.62]
(Figure 2c, d).
Similar activated CD4+ and CD8+ T cell proportions were
shown by patients with genotypes 1–4 and patients with genotypes
2–3 [HLA-DR+/CD38+/CD4+, genotypes 1–4: 25.26, (IQR
15.94–45.87) - genotypes 2–3: 31.34, (IQR 14.94–44.47),
p=0.986; HLA-DR+/CD38+/CD8+, genotypes 1–4: 39.95,
(IQR 26.94–58.21) – genotypes 2–3: 41.53, (IQR 22.39–58.7),
p=0.914] (Figure 2e, f).
Immune activation and MT according to EVR to anti-HCV
treatment
To address the association of peripheral T cell activation with
the outcome of peg-INF-alpha/ribavirin anti-HCV treatment, we
also analyzed HLA-DR+CD38+CD4+ and CD8+ T cells in EVR
and NR patients.
Median HLA-DR+CD38+CD4+ and CD8+ were similar in
both groups, (HLA-DR/CD38+/CD4+, EVR 34.1 (IQR 19.3–
48.3) – NR 35.4 (IQR 26–66.7), p=0.097; HLA-DR/CD38+/
CD8+, EVR 51.2 (IQR 27.2–65.9) – NR 50.5 (IQR 35.2–76.1),
p=0.309) (Figure 3a, b).
In addition, to assess potential interactions between MT and
virological response to anti-HCV treatment, baseline LPS and
sCD14 levels were compared between EVR subjects and NR
(Figure 4a, b). Interestingly, EVR patients presented significantly
lower median sCD14 (EVR 2.73, IQR: 2.18–3.25 – NR 3.8, IQR:
2.9–4.4, p=0.0001) (Figure 4a), despite no differences in median
LPS levels between patients (EVR 178.7, IQR: 150.7–298.3 – NR
197.7, IQR: 88.4–327.4, p=0.865), (Figure 4b).
Identification of factors associated to EVR to anti-HCV
treatment
Given that the host response to MT expressed by sCD14 was
lower in EVR patients at baseline, we investigated its association
with EVR after adjustment for demographic and HCV-related
variables. Table 2 shows results from univariate and multivariate
analyses.
In the univariate analysis, higher sCD14 was associated with a
reduced probability of reaching EVR (OR 0.419 for each sCD14
unit more, 95%CI 0.252–0.695, p=0.001), whereas no associa-
tion was shown between LPS and EVR (OR 1.000 for each LPS
unit more, 95%CI 0.996–1.004, p=0.934). As expected, HCV
genotypes 1–4 (OR 0.109 versus HCV genotypes 2–3, 95%CI
0.037–0.324, p=0.0001), higher HCV viral load (OR 0.409 for
each log10 IU/mL more, 95%CI 0.207–0.809, p=0.01), and
cirrhosis (OR 0.382 versus absence of cirrhosis, 95%CI 0.148–0.99,
p=0.048) were all associated to a decreased chance of EVR
(Table 2).
In line with univariate data, the proportion of patients with
cirrhosis were more likely to fail EVR (cirrhosis/NR=48%,
cirrhosis/EVR=26%, p=0.044); similarly a higher proportion of
genotype 1–4 patients did not reach EVR (genotype 1–4/
NR=81%, genotype 1–4/EVR=32%, p=0.0001). No differ-
ences were shown in EVR/NR according to the presence fibrosis
(p=0.162).
Significantly predictive parameters in the univariate analysis
entered the logistic regression model adjusted for age, sex and
baseline CD4+ T cell count (Table 2).
Overall, multivariate analysis shown in Table 2 was performed
in 65/98 patients for whom both LPS and sCD14 data were
available. Baseline characteristics of these 65 patients were
comparable to the entire cohort.
In the adjusted model, higher sCD14 levels (AOR 0.145 for
each unit more, 95%CI 0.031–0.688, p=0.015) was confirmed as
predictive independent marker of decreased chances of EVR
(Table 2). No other demographic or HCV related variable that we
studied resulted independently associated with EVR (Table 2).
Similar results were obtained also excluding from the analyses
the 8/98 patients who did not reach 12 weeks follow up (data not
shown).
Baseline characteristics of the study population
according to SVR
SVR data were available for 88 subjects. Ten patients have not
reached the end of the study at the time of analysis.
Overall, 41 patients (46.6%) exhibited SVR. Table 3 shows the
clinical, epidemiological, and laboratory data of the patients under
study according to SVR. Patients achieving and not achieving
SVR were comparable for baseline demographic parameters
(Table 3). Indeed, even if baseline CD4+ T cells were similar, SVR
subjects presented higher CD4+ nadir and higher current CD8+,
compared to N-SVR (median, IQR: nadir CD4+ T cells SVR
212/mL, 120–268 – N-SVR 131/mL, 45–198, p=0.025; CD8+ T
cells SVR 693/mL, 558–1048.5 – N-SVR 540/mL, 383–952,
p=0.030) (Table 3).
Similarly to EVR patients, SVR subjects were characterized by
a baseline milder liver disease: in fact, in comparison with N-SVR
patients, they showed lower baseline median HCV viremia (HCV-
RNA, 5.3 log10 cp/mL, IQR: 4.7–5.9 versus 5.68 log10 cp/mL,
IQR: 5.3–6.2; p=0.014) and they more rarely presented cirrhosis
(9/41, 22% vs 19/44, 43%, p=0.037). In the same way, HCV
genotypes 1–4 were more represented in N-SVR patients (SVR 7,
17% - N-SVR 33, 70%, p=0.0001) (Table 3).
We then investigated the predictive value of EVR on SVR in
our patients: the positive predictive value of EVR for the
achievement of SVR was 64.1% (41 EVR patients who reached
SVR/64 EVR patients who reached the end of the study), on the
contrary the negative predictive value was 100% (all 24 NR did
not show sustained virological response).
T cell activation, MT and host response to MT according
to SVR to anti-HCV treatment
Peripheral T lymphocytes activation was similar in both groups
(HLA-DR/CD38+/CD4+, SVR 30.8 (IQR 18.1–39.2) – N-SVR
25.3 (IQR 15.5–54), p=0.933; HLA-DR/CD38+/CD8+, SVR
41 (IQR 29.3–56.6) – N-SVR 40 (IQR 26.5–62.5), p=0.855)
(Figure 3c, d).
On the contrary, SVR patients were characterized by lower
sCD14 and LPS levels, reaching statistical significance for sCD14
sCD14 Predicts Response to Anti-HCV Therapy
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32028Figure 2. Activated HLA-DR+CD4+ and CD8+ T-cells according to liver fibrosis, cirrhosis and HCV genotypes. a)-b) Activated HLA-
DR+CD4+ and CD8+ T-cells were compared between patients with advanced fibrosis (AF) and non advanced fibrosis (N-AF). c)-d) Activated HLA-
DR+CD4+ and CD8+ T-cells were compared between patients with cirrhosis and absence of cirrhosis (N-Cirrhosis). e)-f) Activated HLA-DR+CD4+ and
CD8+ T-cells were compared between patients with HCV genotypes 1–4 and genotypes 2–3. Each point represents the value from one subject’s
plasma. Activated HLA-DR+CD4+ and CD8+ T-cells % values are presented. AF=advanced fibrosis – N-AF=non advanced fibrosis. p-values were
assessed by Mann Whitney U test. p.0.05 was considered non significant (NS).
doi:10.1371/journal.pone.0032028.g002
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32028(median, IQR: sCD14 SVR 2.61, 2.14–3.33 – N-SVR 3.11, 2.49–
3.97, p=0.026; LPS SVR 173.9, 151.6–243.9 – N-SVR 232.9,
148.7–330.3, p=0.164) (figure 4c, d).
Identification of predictors of SVR to anti-HCV treatment
To investigate the possible predictive value of MT on SVR, we
conducted a logistic regression analysis including HIV and HCV
related variables and both LPS and sCD14 (Table 4).
Interestingly, in the univariate model, higher circulating sCD14
and LPS are associated with a reduced chance of SVR, reaching
significance for sCD14 (OR 0.668 for each sCD14 unit more,
95%CI 0.428–1.041, p=0.046; OR 0.996 for each LPS unit
more, 95%CI 0.990–1.001, p=.106). In addition, several HCV
parameters were related to SVR: HCV genotypes 1–4 (OR 0.087
versus HCV genotypes 2–3, 95%CI 0.031–0.244, p=0.0001),
HCV viral load (OR 0.423 for each log10 IU/mL more, 95%CI
0.224–0.798, p=0.008), and cirrhosis (OR 0.37 versus absence of
cirrhosis, 95%CI 0.143–0.957, p=0.04) were predictive of a
reduced probability of SVR in the univariate model.
In line with univariate data, the proportion of patients with
cirrhosis were more likely to fail SVR (cirrhosis/N-SVR=43%,
cirrhosis/SVR=22%, p=0.037); similarly a higher proportion of
genotype 1–4 patients did not reach SVR (genotype 1–4/N-
SVR=70%, genotype 1–4/SVR=17%, p=0.0001). No differ-
ences were shown in SVR/N-SVR according to the presence
fibrosis (p=0.114).
We next performed multivariate analysis in 65/98 patients for
whom both LPS and sCD14 data were available (Table 4).
Baseline characteristics of these 65 patients were comparable to
the entire cohort. In multivariate logistic regression, the most
important predictive parameter of SVR was HCV genotype (AOR
0.022 HCV genotypes 1–4 versus 2–3, 95%CI 0.001–0.469,
p=0.014). No further measures of MT and immune response to
MT that we measured were independently associated with SVR
(Table 4).
Similar results were obtained also excluding from the analyses
the 8/98 patients who were lost at follow up before 12 weeks (data
not shown).
Results were similar in a sensitivity analysis including only
HIV/HCV co-infected patients on HAART (n=96): despite
comparable LPS, EVR patients presented lower sCD14 than NR
(median, IQR: sCD14 EVR 2.74, 2.18–3.26 – NR 3.75, 2.89–
4.15, p=0.0001; LPS EVR 178.7, 150.7–298.3 – NR 195.8, 75–
321.9, p=0.649 (Figure S1a, b).
Figure 3. Activated HLA-DR+CD4+ and CD8+ T-cells according to EVR and SVR. a)-b) Activated HLA-DR+CD4+ and CD8+ T-cells were
compared between patients with early virological response [EVR, i.e. undetectable serum HCV-RNA (,50 IU/mL) or $2 log10 reduction from baseline
after 12 weeks of therapy], and Null Responders (NR) (i.e. serum HCV-RNA $50 IU/mL and ,2 log10 reduction from baseline). c)-d) Activated HLA-
DR+CD4+ and CD8+ T-cells were compared between patients with sustained virological response [SVR, i.e. undetectable serum HCV-RNA (,50 IU/
mL) 24 weeks after the end of a full course of 48 or 72 weeks of anti-HCV treatment, according to genotype], and N-SVR subjects. Each point
represents the value from one subject’s plasma. Activated HLA-DR+CD4+ and CD8+ T-cells % values are presented. p-values were assessed by Mann
Whitney U test. p.0.05 was considered non significant (NS).
doi:10.1371/journal.pone.0032028.g003
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to N-SVR (median, IQR: sCD14 SVR 2.63, 2.15–3.37 – N-SVR
3.06, 2.48–3.87, p=0.041; LPS SVR 173.9, 151.6–243.9 – N-
SVR 214.1, 145.3–329.5, p=0.213) (Figure S1c, d).
Furthermore, sCD14 confirmed independently associated with
EVR (Tables S1 and S2).
Discussion
In cART-treated HIV/HCV co-infected patients we show: (i)
greater host responsiveness to LPS in patients with most aggressive
HCV-related liver disease and harboring HCV genotypes 1–4; (ii)
low levels of LPS/sCD14 as predictors of virological response to 3
months of anti-HCV treatment (i.e. EVR).
Response to anti-HCV therapy is less satisfactory in HIV/
HCV-co-infected individuals, urging the identification of predic-
tive outcome markers.
There is increasing evidence that MT and MT-driven immune
activation are pathogenetic mechanisms of alcohol-driven liver
disease [35,36], and of hepatic disease progression in HBV and
HCV mono-infection as well as in HIV/HCV co-infection
[27,33].
In line with this hypothesis, our data show that HIV/HCV co-
infected patients with cirrhosis display higher circulating sCD14
that is a marker of MT-driven immune activation [24,27].
Having shown the association between heightened circulating
sCD14 and most advanced liver disease, we next aimed to
investigate whether MT and the host response that it elicits could
condition short- and long- term virological outcome to anti-HCV
treatment.
Our major finding is that, despite equal MT in HIV/HCV co-
infected patients with and without EVR, a contained host response
to translocated microbial by-products as measured by low levels of
circulating sCD14, independently predicts EVR.
As for HCV-related factors, only HCV genotype was confirmed
to independently affect response to antiviral treatment. Although
the effect of HCV genotypes on HCV/HIV pathogenesis, disease
progression and response to therapy are largely unknown,
genotypes 1–4 are commonly defined as difficult-to-treat given
the much lower probability of response to conventional HCV
therapy [37,38]. Interestingly, patients displaying HCV genotypes
1–4 also presented elevated sCD14 levels. This association
remained significant also excluding from the analysis patients
characterized by severe forms of liver disease, suggesting that
Figure 4. Circulating sCD14 and LPS levels are higher in NR and in N-SVR patients. a)-b) sCD14 and LPS were compared between patients
with early virological response [EVR, i.e. undetectable serum HCV-RNA (,50 IU/mL) or $2 log10 reduction from baseline after 12 weeks of therapy],
and Null Responders (NR) (i.e. serum HCV-RNA $50 IU/mL and ,2 log10 reduction from baseline). c)-d) sCD14 and LPS were compared between
patients with sustained virological response [SVR, i.e. undetectable serum HCV-RNA (,50 IU/mL) 24 weeks after the end of a full course of 48 or 72
weeks of anti-HCV treatment, according to genotype], and N-SVR subjects. Each point represents the value from one subject’s plasma. sCD14 and LPS
were measured in plasma samples; sCD14 mg/mL, LPS pg/mL. p-values were assessed by Mann Whitney U test. p.0.05 was considered non
significant (NS).
doi:10.1371/journal.pone.0032028.g004
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heightened immune activation, possibly due to MT.
Immune activation has been suggested to accelerate liver disease
in HIV/HCV co-infection, in turn limiting response to therapy
[13,39,40]. In our study, activated HLA-DR+CD38+ T cells were
increased in comparison with levels of HIV mono-infected patients
and healthy subjects reported in literature [41], and yet they failed
significant association with HCV genotypes, liver disease and
virological response to anti-HCV treatment.
On the contrary, by showing higher sCD14 levels in NR
patients, our data indicate enhanced activation of innate immunity
as possible correlate of failing response to therapy, that might be
secondary to increased MT.
However, should MT be indeed a relevant pathway in
conditioning anti-HCV response through its effect in triggering
excessive immune activation, one would expect a parallel
expansion in markers of cellular and innate immune activation
[24,42]. At least two non-mutually exclusive reasons might explain
the seemingly discrepant trend in activated CD8+ and sCD14
levels. A first consideration is that the large majority of our patients
were on long-term HAART with undetectable HIV-RNA, that is
a known major determinant of T cell activation [43]. Secondly,
HCV infection triggers immune activation mainly in monocytes
and liver-residing macrophages, the activation of which sustains
liver inflammation [40]. Given the role of hepatic Kupffer cells in
detoxification of bloodstream bacterial components, high levels of
microbial products in the bloodstream and in the liver with its
consequent down-stream effects can be one of the mechanisms
involved in reduced control of virus replication after anti-HCV
treatment. Therefore, a unique pro-inflammatory/activated milieu
might be speculated within the liver that fails to be detected by
means of peripheral blood investigation. According to this model,
Sandler et al. recently described high density of CD14+CD68+ in
Table 2. Association between markers of microbial
translocation and Early Virological Response to anti-HCV
treatment.
Univariate Multivariate
OR 95%CI P AOR 95%CI p
LPS (pg/mL) 1.000 0.996–1.004 0.934 0.997 0.99–1.004 0.345
sCD14 (mg/mL) 0.419 0.252–0.695 0.001 0.145 0.031–0.688 0.015
HCV genotypes
(1–4 vs 2–3)
0.109 0.037–0.324 0.0001 0.233 0.021–2.618 0.238
HCV-RNA
(log10 IU/mL)
0.409 0.207–0.809 0.01 0.789 0.134–4.628 0.793
Fibrosis
(advanced vs non
advanced)
0.504 0.191–1.327 0.165 0.134 0.005–3.879 0.616
Cirrhosis (yes vs
no)
0.382 0.148–0.99 0.048 0.185 0.007–4.623 0.304
Nadir CD4+ T
cells/mL
1.003 0.999–1.006 0.155 1.007 0.998–1.016 0.134
CD4+ T cells/mL 0.999 0.997–1.002 0.518 0.996 0.990–1.001 0.112
Age, years 1.043 0.948–1.149 0.386 1.134 0.879–1.463 0.333
Sex, male vs
female
0.509 0.134–1.934 0.321 0.215 0.007–6.926 0.385
LEGEND. LPS, soluble CD14, CD4+ T cells/mL, age, HCV-RNA log10 cp/mL for
each unit more. sCD14 and LPS were measured in plasma samples; sCD14 mg/
mL, LPS pg/mL. Multivariate analysis was performed in 65/98 patients for whom
all the clinical, epidemiological and biological parameters under study were
available.
OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. p.0.05 was
considered non significant.
doi:10.1371/journal.pone.0032028.t002
Table 3. Baseline demographic and immuno-virological
characteristics of patients according SVR.
Characteristics SVR (41) N-SVR (47) p
Age, years * 44 (40–47.5) 43 (42–46) 0.997
Gender, male u 33 (80) 40 (85) 0.565
Time since 1
st diagnosis of HIV,
(years)*
18 (13–22) 18 (15–20) 0.700
Duration of HAART, (years) * 10 (5–14) 11 (9–13) 0.192
HAART u 0.849
naive 1 (2) 1 (2)
NNRTI+NRTI 7 (17) 5 (11)
NRTI+PI 30 (73) 37 (79)
other 3 (7) 4 (8)
Exposure cathegoriesu 0.300
MSM 2 (5) 0
WSM 2 (5) 3 (6)
IDUs 37 (90) 44 (94)
Previous AIDS diagnosis u 8/39 (21) 13/44 (30) 0.345
CD4+ T cells/mL nadir * 131 (45.2–198) 0.025
Baseline CD4+ T cells/mL * 467 (326.5–574) 398 (300–582) 0.281
CD4 T cells % * 26.3 (21.5–32.1) 27.5 (20–34) 0.977
CD8 T cells/mL * 693 (558–1048.5) 540 (383–952) 0.030
CD8 T cells % * 41.1 (35.8–49.5) 40.4 (33.6–47) 0.315
Baseline HIV-RNA log10 cp/mL * 1.7 1.7 0.934
Time to HIV-RNA ,40 cp/mL (mts)* 43 (15–72) 42 (21–69) 0.986
HCV genotypes u 0.0001
1–4 7 (17) 33 (70)
2–3 36 (88) 14 (30)
Baseline HCV-RNA log10 IU/mL * 5.3 (4.7–5.9) 5.68 (5.3–6.2) 0.014
Cirrhosis u 9/41 (22) 19/44 (43) 0.037
Advanced fibrosis u 15/39 (38) 23/41 (56) 0.114
HBV infection (HBsAg+) u 2 (5) 4 (9) 0.681
Serum AST (UI/L) * 69 (44–94.5) 69 (42–103) 0.812
Serum ALT (UI/L)* 97 (56.5–170) 85 (55–127) 0.268
BMI * 22.3 (21.1–24.5) 23.1 (21.2–25.2) 0.495
Glycemia (mg/dL) * 89 (82–93) 89 (83–97.7) 0.740
Insulinemia (UI/L) * 12.4 (7.1–20.3) 13.4 (9.7–21.2) 0.713
Alcol (gr/die) * 0 (0–20) 0 (0–5) 0.611
HOMA index * 2.3 (1.5–3.8) 3.1 (1.8–4.6) 0.190
LEGEND. Data are presented as *median, (IQR) and uabsolute number, (%).
Differences between groups were compared by *Mann Whitney U test and ux2
test. N-SVR, Non Sustained Virological Response: serum HCV-RNA ($50 IU/mL)
24 weeks after the end of a full course of 48 or 72 weeks of anti-HCV treatment.
SVR, Sustained Virological Response: undetectable serum HCV-RNA ,50 UI/mL
24 weeks after the end of a full course of 48 or 72 weeks of anti-HCV treatment.
NRTI, Nucleoside Reverse Transcriptase Inhibitors; NNRTI, Non Nucleoside
Reverse Transcriptase Inhibitors; PI, Protease Inhibitors; MSM, men who have
sex with men; WSM, women who have sex with men; IDUs, injection drug users;
HCV, hepatitis C virus; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen;
AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; BMI, Body
Mass Index. HOMA index, Homeostatic Model Assessment index.
doi:10.1371/journal.pone.0032028.t003
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suggestive for LPS-driven activation of hepatic Kupffer cells [27].
Our findings suggest that the host response to increased MT
might play a central role in the pathogenesis of HIV/HCV-related
liver injury, and in the inappropriate response to therapy, allowing
to speculate a vicious cycle, whereby HIV effects on the gut mucosa
might enhance MT which stimulate hepatic fibrosis/cirrhosis with
consequent portal systemic shunt, to further fuel MT.
However, when we investigated the independent effect of MT
on long-term response to therapy, sCD14 was still associated to
SVR in the univariate analysis, but lost independent predictive
value in the multivariable model, suggesting that immune response
to MT might play a role in the earlier phases of treatment. Because
EVR conditions SVR, this could underline the importance of
assessing (and controlling) MT before starting anti-HCV therapy.
In the present study, we analysed only circulating sCD14 as
marker of monocyte activation, and as possible reflection of MT.
The investigation of additional markers of monocyte activation
(e.g. soluble CD163) and systemic inflammation (e.g. IL-6) will
help gain a broader definition of the effect of systemic immune
activation/inflammation on HCV disease progression and re-
sponse to therapy.
As alternative hypothesis, increased sCD14 in patients with worst
liver disease and HCV genotype 1–4 might reflect heightened
endogenous interferon (IFN) rather than increased MT. Indeed,
HCV infection activates the endogenous IFN system in the liver
[44]; yet such gene pre-activation is associated to the lack of
response to IFN-alpha/ribavirin, possibly through a refractory state
to IFN-mediated signalling [45–48]. Patients harbouring HCV
genotypes 1–4 have a higher likelihood of failing EVR/SVR and
have higher levels of endogenous IFN and IFN-stimulated gene
(ISG) expression [18,49]. Given that the exposure to IFN has been
shown to transiently activate macrophages with sCD14 release [50],
and that CD14+ monocytes of HIV-infected patients display higher
ISG expression [51], our data that patients with cirrhosis, 1–4
genotypes and non-responders show increased sCD14 despite equal
plasma LPS, allow to hypothesise in these individuals an overall
higher innate immune activation with higher endogenous IFN, that
results in sCD14 release, while rendering the cells less sensitive to
exogenous IFN.
Some limitations of our study need to be discussed. Our
research focused on HIV/HCV co-infected patients. However,
given that hepatocytes are a major source of sCD14, a control
group of HCV mono-infected individuals would help establish
cause-effect nexus between the host response to MT and severity
of liver disease and response to therapy in the setting of HCV/
HIV co-infection.
Nevertheless, despite our study was not specifically designed to
establish causality, it well adds to the debate on the role of
microbial translocation and its downstream effects of immune
activation in the setting of HCV infection and disease. In
particular, our findings expands on data by both by Sandler
et al. in HCV mono-infected patients showing elevated circulating
sCD14 as independent predictor of end-stage liver disease [27],
and Balagopal et al. in HIV/HCV co-infected patients correlating
elevated sCD14/LPS with cirrhosis [33], as they strongly suggest
an independent influence of immune activation due to MT in the
outcome of anti-HCV treatment.
A further limitation of our research is that, despite associating
with EVR, augmented sCD14 seemingly fail to influence sustained
response to therapy, in turn limiting its exploitation in the clinical
practice as measure to a priori include/exclude patients from
treatment.
Knowing the prognostic significance of EVR for SVR, larger
studies are needed to shed light on MT in HIV/HCV co-infection
pathogenesis and response to therapy, essential premise to evaluate
the possibility of novel therapeutic adjuvant interventions targeting
translocation of bacterial products in peripheral blood ant its
downstream effects.
Supporting Information
Figure S1 Circulating sCD14 and LPS levels are higher
in NR and in N-SVR patients on HAART. Results from a
sensitivity analysis including only HIV/HCV co-infected patients
on HAART (n=96) are shown. a)-b) sCD14 and LPS were
compared between patients with early virological response [EVR,
i.e. undetectable serum HCV-RNA (,50 IU/mL) or $2 log10
reduction from baseline after 12 weeks of therapy], and Null
Responders (NR) (i.e. serum HCV-RNA $50 IU/mL and ,2
log10 reduction from baseline). c)-d) sCD14 and LPS were
compared between patients with sustained virological response
[SVR, i.e. undetectable serum HCV-RNA (,50 IU/mL) 24
weeks after the end of a full course of 48 or 72 weeks of anti-HCV
treatment, according to genotype], and N-SVR subjects.
(TIF)
Table S1 Association between markers of microbial
translocation and Early Virological Response to anti-
HCV treatment on patients on HAART. Univariate and
multivariate logistic regression conducted including only HIV/
HCV patients on HAART (n 96) to explore association between
markers of microbial translocation (sCD14 and LPS) and EVR.
The multivariate analysis is adjusted for demographic, HCV- and
HIV-related variables. LPS, soluble CD14, CD4+ T cells/mL, age,
Table 4. Association between markers of microbial
translocation and Sustained Virological Response to anti-HCV
treatment.
Univariate Multivariate
OR 95%CI p AOR 95%CI p
LPS (pg/mL) 0.996 0.990–1.001 0.106 1.000 0.980–1.003 0.129
sCD14 (mg/mL) 0.668 0.428–1.041 0.046 0.584 0.214–1.589 0.292
HCV genotypes
(1–4 vs 2–3)
0.087 0.031–0.244 0.0001 0.022 0.001–0.469 0.014
HCV-RNA
(log10 IU/mL)
0.423 0.224–0.798 0.008 0.778 0.309–10.231 0.519
Fibrosis
(advanced vs non
advanced)
0.498 0.200–1.194 0.116 0.553 0.026–11.663 0.703
Cirrhosis
(yes vs no)
0.370 0.143–0.957 0.040 0.161 0.007–4.472 0.289
Nadir CD4+
T cells/mL
1.003 1.000–1.006 0.071 1.005 0.997–1.014 0.835
CD4+ T cells/mL 1.001 0.999–1.003 0.287 1.000 0.995–1.009 0.669
Age, years 0.996 0.908–1.093 0.996 0.942 0.719–1.236 0.870
Sex, male vs
female
0.722 0.237–2.200 0.566 0.812 0.067–9.871 0.216
LEGEND. LPS, soluble CD14, CD4+ T cells/mL, age, HCV-RNA log10 cp/mL for
each unit more. sCD14 and LPS were measured in plasma samples; sCD14 mg/
mL, LPS pg/mL. Multivariate analysis was performed in 65/98 patients for whom
all the clinical, epidemiological and biological parameters under study were
available.
OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. p.0.05 was
considered non significant.
doi:10.1371/journal.pone.0032028.t004
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were measured in plasma samples; sCD14 mg/mL, LPS pg/mL.
OR, odds ratio; AOR, adjusted odds ratio; CI, confidence
interval. p.0.05 was considered non significant.
(DOC)
Table S2 Association between markers of microbial
translocation and Sustained Virological Response to
anti-HCV treatment on patients on HAART. Univariate
and multivariate logistic regression conducted including only
HIV/HCV patients on HAART (n 96) to explore association
between markers of microbial translocation (sCD14 and LPS) and
SVR. The multivariate analysis is adjusted for demographic,
HCV- and HIV-related variables. LPS, soluble CD14, CD4+ T
cells/mL, age, HCV-RNA log10 cp/mL for each unit more. sCD14
and LPS were measured in plasma samples; sCD14 mg/mL, LPS
pg/mL. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence
interval. p.0.05 was considered non significant.
(DOC)
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